Fighting Covid-19: NPPA highlights DGFT notification banning Hydroxychloroquine export

Our Bureau New Delhi | Updated on April 06, 2020 Published on April 06, 2020

Tweet comes amidst speculations over whether Trump’s request for the drug being used to fight Covid-19 will be met by India

The National Pharmaceutical Pricing Authority, on Monday, highlighted through its twitter account, a government order notified on April 4 that completely prohibits export of Hydroxychloroquine from India, without any exceptions.

The timing of the NPPA’s tweet is important as US President Donald Trump, at a White House press conference on Saturday, said that he had sought Prime Minister Narendra Modi’s help for release of the orders of Hydroxychloroquine placed by the US.

Modi and Trump had a teleconference to discuss Covid-19 issues on Saturday.


“Prime Minister Modi did not make any commitments to the US President for releasing the Hydroxychloroquine ordered by the country. At this time of crisis, national interest is of paramount importance, and any decision on the matter will be taken after due consideration,” a government official told BusinessLine.

On March 25, the Directorate General of Foreign Trade (DGFT) had already passed a notification prohibiting the export of Hydroxychloroquine — an anti-malarial drug that is now being widely used to treat the coronavirus.

However, there were a few exceptions to the ban which includes allowing exports of orders placed before the notification of the ban, exports on humanitarian grounds and exports from Special Economic Zones.

On April 4, the DGFT amended the earlier notification and prohibited exports of Hydroxychloroquine completely without any exceptions.

“The export of Hydroxychloroquine and formulations made from Hydroxychloroquine....is no longer allowed from SEZs/EOUs or against Advance Authorisations or under the Para 1.05(b) of Foreign Trade Policy 2015-10 or against full advance payment as specified in Para 2 of the Notification (dated March 25 2020). The export of Hydroxychoroquine and formulations made from Hydroxychloroquine, therefore, shall remain prohibited, without any exception,” the notification stated.

Published on April 06, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.